Abstract
Introduction: Several antiepileptic drugs are available for the treatment of epileptic patients. However, the treatment of some seizure types and novel drug formulations deserve further advances in epilepsy research. Areas covered: The authors analyze the published evidence on the efficacy of perampanel against secondarily generalized seizures (SGS) and report the currently available development of intravenous (IV) formulations of carbamazepine (CBZ), commenting on their potential in the clinical setting. Expert opinion: Perampanel is the first noncompetitive AMPA receptor antagonist to be approved as adjunctive treatment in patients with partial-onset (focal) seizures (POS) with or without secondary generalization. Apart from its efficacy and safety on POS, a consistent body of evidence supports its efficacy in SGS at a minimum dose of 8 mg/day; however, such dose appears close to the best-tolerated dose. CBZ is a poorly water-soluble compound; many efforts to develop a parenteral formulation have not been successful so far. Novel IV CBZ formulations seem to exhibit favorable pharmacokinetics along with good tolerability in animal models and in patients taking oral CBZ. Further studies are needed to assess whether larger doses will be as well tolerated, allowing IV CBZ to be used as bridge therapy when the oral route is not feasible or in patients naïve to CBZ.
| Original language | English |
|---|---|
| Pages (from-to) | 637-644 |
| Number of pages | 8 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 15 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Epilepsy
- Intravenous carbamazepine
- Perampanel
- Secondarily generalized seizures
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
Cite this
Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. / Franco, Valentina; Iudice, Alfonso; Grillo, Elisabetta; Citraro, Rita; De Sarro, Giovambattista; Russo, Emilio.
In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 5, 2014, p. 637-644.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures
AU - Franco, Valentina
AU - Iudice, Alfonso
AU - Grillo, Elisabetta
AU - Citraro, Rita
AU - De Sarro, Giovambattista
AU - Russo, Emilio
PY - 2014
Y1 - 2014
N2 - Introduction: Several antiepileptic drugs are available for the treatment of epileptic patients. However, the treatment of some seizure types and novel drug formulations deserve further advances in epilepsy research. Areas covered: The authors analyze the published evidence on the efficacy of perampanel against secondarily generalized seizures (SGS) and report the currently available development of intravenous (IV) formulations of carbamazepine (CBZ), commenting on their potential in the clinical setting. Expert opinion: Perampanel is the first noncompetitive AMPA receptor antagonist to be approved as adjunctive treatment in patients with partial-onset (focal) seizures (POS) with or without secondary generalization. Apart from its efficacy and safety on POS, a consistent body of evidence supports its efficacy in SGS at a minimum dose of 8 mg/day; however, such dose appears close to the best-tolerated dose. CBZ is a poorly water-soluble compound; many efforts to develop a parenteral formulation have not been successful so far. Novel IV CBZ formulations seem to exhibit favorable pharmacokinetics along with good tolerability in animal models and in patients taking oral CBZ. Further studies are needed to assess whether larger doses will be as well tolerated, allowing IV CBZ to be used as bridge therapy when the oral route is not feasible or in patients naïve to CBZ.
AB - Introduction: Several antiepileptic drugs are available for the treatment of epileptic patients. However, the treatment of some seizure types and novel drug formulations deserve further advances in epilepsy research. Areas covered: The authors analyze the published evidence on the efficacy of perampanel against secondarily generalized seizures (SGS) and report the currently available development of intravenous (IV) formulations of carbamazepine (CBZ), commenting on their potential in the clinical setting. Expert opinion: Perampanel is the first noncompetitive AMPA receptor antagonist to be approved as adjunctive treatment in patients with partial-onset (focal) seizures (POS) with or without secondary generalization. Apart from its efficacy and safety on POS, a consistent body of evidence supports its efficacy in SGS at a minimum dose of 8 mg/day; however, such dose appears close to the best-tolerated dose. CBZ is a poorly water-soluble compound; many efforts to develop a parenteral formulation have not been successful so far. Novel IV CBZ formulations seem to exhibit favorable pharmacokinetics along with good tolerability in animal models and in patients taking oral CBZ. Further studies are needed to assess whether larger doses will be as well tolerated, allowing IV CBZ to be used as bridge therapy when the oral route is not feasible or in patients naïve to CBZ.
KW - Epilepsy
KW - Intravenous carbamazepine
KW - Perampanel
KW - Secondarily generalized seizures
UR - http://www.scopus.com/inward/record.url?scp=84896266745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896266745&partnerID=8YFLogxK
U2 - 10.1517/14656566.2014.879572
DO - 10.1517/14656566.2014.879572
M3 - Article
C2 - 24437529
AN - SCOPUS:84896266745
VL - 15
SP - 637
EP - 644
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 5
ER -